The central role of the chemokine receptor, CXCR4, in haemopoietic stem cell transplantation: will CXCR4 antagonists contribute to the treatment of blood disorders?

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Recent clinical trials have used CXCR4 antagonists for the rapid mobilization of CD34(+) haemopoietic stem/progenitor cells (HSC/HPC) from the bone marrow to the blood in patients refractory to granulocyte-colony-stimulating factor (G-CSF). These antagonists not only mobilize non-cycling cells with a higher proportion of repopulating cells, but also enhance CD34(+) cell mobilization when used in combination with G-CSF. Here, we review the importance of CXCR4 and its ligand CXCL12 in haemopoiesis, and the potential roles of CXCR4 antagonists in the clinical HSC transplant setting.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Vox Sang.

Title: Vox sanguinis

Publisher: Wiley

ISSN: 0042-9007

ISSN (Print): 0042-9007

Publication date (Electronic): Jan 2008

Volume: 94

Issue: 1

Affiliations

[1 ] Stem Cells and Immunotherapies, NHS Blood and Transplant, John Radcliffe Hospital, Headington, Oxford, UK and Nuffield Department of Clinical Laboratory Sciences, University of Oxford, Oxford, UK.

Article

Publisher Item ID: VOX995

DOI: 10.1111/j.1423-0410.2007.00995.x

PubMed ID: 18042197

SO-VID: a03349ce-a6a1-4c92-a33d-95ea42660c99

History

Data availability:

Comments

Comment on this article

scite_

Cited by 3

See all cited by